Why the study?
Do circulating MMP-2, -3, and -9 predict kidney disease progression in non-diabetic patients with coronary artery disease?
Do circulating MMP-2, -3, and -9 predict kidney disease progression in non-diabetic patients with coronary artery disease?
Circulating MMP-2, -3, and -9 levels may serve as novel biomarkers for predicting kidney disease progression in non-diabetic patients with coronary artery disease.
MMP levels may refine kidney risk prediction in non-diabetic CAD; leaves open validation and therapeutic implications in prospective studies.
Circulating MMP-2, -3 and -9 are independently associated with kidney disease progression in non-diabetic CAD patients and add incremental predictive power to conventional risk factors.
No takes yet. Share an insight, caveat, or question.
Hsu et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: